Age ± SD |
54.1 ± 5.1 (43-64) |
|
54.7 ± 6.0 (41-64) |
|
0.45 |
IPSS ± SD |
29.2 ± 1.6 (25-33) |
24.2 ± 1.1 (2222. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L: Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six Europeancountries. BJU Int. 2006; 97: 96-100.
23. Abdel-Aziz KF, Lemack GE: Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep. 2002; 3: 445-51.
24. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006; 49: 651-8.
25. Armitage J, Emberton M: The role of anticholinergic drugs in men with lower urinary tract symptoms. Curr Opin Urol. 2008; 18: 11-5.
26. Roehrborn CG: Definition of at-risk patients: baseline variables. BJU Int. 2006; 97: 7-11; discussion 21-2.
27. Martín-Merino E, García-Rodríguez LA, Massó-González EL, Roehrborn CG: Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009; 182: 1442-8.
28. Layton D, Pearce GL, Shakir SA: Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 2001; 24: 703-13.
29. Wagg A, Compion G, Fahey A, Siddiqui E: Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012; 110: 1767-74.-3030. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I: Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol. 1999; 162: 376-82.) |
28.8±2.4 (23-33) |
16.0±1.2 (1414. Miller SW, Miller MS: Urological disorders in men: urinary incontinence and benign prostatic hyperplasia. J Pharm Pract. 2011; 24: 374-85.
15. Polido Júnior A, Costa JM, Munhoz T, Sampaio FJ, Cardoso LE, Amaro JL: Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusoroveractivity. Int Urogynecol J. 2010; 21: 1539-44.
16. Gollar KM, Young DG, Bailen J, He W, Forero-Schwanhaeuser S: Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients byduration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urol Nurs. 2012; 32: 38-46, 50.
17. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z: Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65: 487-507.
18. H Saito, Takumi Y, Hiroyuki O, Takashi M, Toshiyuki M, Shin'ichi T, et al.: A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999; 12: 525-36.
19. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169: 2253-6
20. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et al.: Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeuticsystem formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005; 174: 1334-8.-2121. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004; 94: 817-20.) |
P < 0.05 |
IPSS4 ± SD |
17.6 ± 1.0 (1515. Polido Júnior A, Costa JM, Munhoz T, Sampaio FJ, Cardoso LE, Amaro JL: Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusoroveractivity. Int Urogynecol J. 2010; 21: 1539-44.
16. Gollar KM, Young DG, Bailen J, He W, Forero-Schwanhaeuser S: Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients byduration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urol Nurs. 2012; 32: 38-46, 50.
17. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z: Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65: 487-507.
18. H Saito, Takumi Y, Hiroyuki O, Takashi M, Toshiyuki M, Shin'ichi T, et al.: A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999; 12: 525-36.-1919. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169: 2253-6) |
16.1 ± 1.0 (1313. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20: 327-36.
14. Miller SW, Miller MS: Urological disorders in men: urinary incontinence and benign prostatic hyperplasia. J Pharm Pract. 2011; 24: 374-85.
15. Polido Júnior A, Costa JM, Munhoz T, Sampaio FJ, Cardoso LE, Amaro JL: Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusoroveractivity. Int Urogynecol J. 2010; 21: 1539-44.
16. Gollar KM, Young DG, Bailen J, He W, Forero-Schwanhaeuser S: Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients byduration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urol Nurs. 2012; 32: 38-46, 50.
17. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z: Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65: 487-507.-1818. H Saito, Takumi Y, Hiroyuki O, Takashi M, Toshiyuki M, Shin'ichi T, et al.: A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999; 12: 525-36.) |
17.1 ± 1.1 (1515. Polido Júnior A, Costa JM, Munhoz T, Sampaio FJ, Cardoso LE, Amaro JL: Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusoroveractivity. Int Urogynecol J. 2010; 21: 1539-44.
16. Gollar KM, Young DG, Bailen J, He W, Forero-Schwanhaeuser S: Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients byduration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urol Nurs. 2012; 32: 38-46, 50.
17. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z: Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65: 487-507.
18. H Saito, Takumi Y, Hiroyuki O, Takashi M, Toshiyuki M, Shin'ichi T, et al.: A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999; 12: 525-36.-1919. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169: 2253-6) |
9.7 ± 1.9 (88. Djavan B, Margreiter M, Dianat SS: An algorithm for medical management in male lower urinary tract symptoms. Curr Opin Urol. 2011; 21: 5-12.
9. Knutson T, Schäfer W, Fall M, Pettersson S, Dahlstrand C: Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting?--A four-year follow-up study. Scand J Urol Nephrol. 2001; 35: 463-9.
10. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001; 166: 550-2; discussion 553.
11. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC: The results of prostatectomy: symptomatic and urodynamic analysis of 152 patients. J Urol. 1979; 121: 640-2.-1212. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al.: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin inpatients with symptomatic overactive bladder. BJU Int. 2004; 93: 303-10.) |
P < 0.05 |
Q8(QoL) ± SD |
5.0 ± 0.7 (44. Chapple C: Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr Opin Urol. 2010; 20: 43-8.
5. Andersson KE: Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003; 62: 3-10.-66. Gallegos PJ, Frazee LA: Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy. 2008; 28: 356-65.) |
5.2 ± 0.9 (33. Abrams P: New words for old: lower urinary tract symptoms for “prostatism”. BMJ. 1994; 308: 929-30.
4. Chapple C: Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr Opin Urol. 2010; 20: 43-8.
5. Andersson KE: Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003; 62: 3-10.-66. Gallegos PJ, Frazee LA: Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy. 2008; 28: 356-65.) |
5.0 ± 0.7 (44. Chapple C: Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr Opin Urol. 2010; 20: 43-8.
5. Andersson KE: Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003; 62: 3-10.-66. Gallegos PJ, Frazee LA: Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy. 2008; 28: 356-65.) |
2.1 ± 0.8 (11. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benignprostatic hyperplasia. J Urol. 1993; 150: 351-8.
2. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z: Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65: 487-507.
3. Abrams P: New words for old: lower urinary tract symptoms for “prostatism”. BMJ. 1994; 308: 929-30.-44. Chapple C: Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr Opin Urol. 2010; 20: 43-8.) |
P < 0.05 |
Qmax ± SD |
8.0 ± 0.9 (99. Knutson T, Schäfer W, Fall M, Pettersson S, Dahlstrand C: Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting?--A four-year follow-up study. Scand J Urol Nephrol. 2001; 35: 463-9.
10. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001; 166: 550-2; discussion 553.
11. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC: The results of prostatectomy: symptomatic and urodynamic analysis of 152 patients. J Urol. 1979; 121: 640-2.-1212. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al.: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin inpatients with symptomatic overactive bladder. BJU Int. 2004; 93: 303-10.) |
9.5 ± 1.1 (88. Djavan B, Margreiter M, Dianat SS: An algorithm for medical management in male lower urinary tract symptoms. Curr Opin Urol. 2011; 21: 5-12.
9. Knutson T, Schäfer W, Fall M, Pettersson S, Dahlstrand C: Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting?--A four-year follow-up study. Scand J Urol Nephrol. 2001; 35: 463-9.
10. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001; 166: 550-2; discussion 553.-1111. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC: The results of prostatectomy: symptomatic and urodynamic analysis of 152 patients. J Urol. 1979; 121: 640-2.) |
8.9 ± 1.1 (77. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008; 20(Suppl 3): S33-43.
8. Djavan B, Margreiter M, Dianat SS: An algorithm for medical management in male lower urinary tract symptoms. Curr Opin Urol. 2011; 21: 5-12.
9. Knutson T, Schäfer W, Fall M, Pettersson S, Dahlstrand C: Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting?--A four-year follow-up study. Scand J Urol Nephrol. 2001; 35: 463-9.
10. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001; 166: 550-2; discussion 553.-1111. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC: The results of prostatectomy: symptomatic and urodynamic analysis of 152 patients. J Urol. 1979; 121: 640-2.) |
10.7 ± 1.3 (99. Knutson T, Schäfer W, Fall M, Pettersson S, Dahlstrand C: Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting?--A four-year follow-up study. Scand J Urol Nephrol. 2001; 35: 463-9.
10. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001; 166: 550-2; discussion 553.
11. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC: The results of prostatectomy: symptomatic and urodynamic analysis of 152 patients. J Urol. 1979; 121: 640-2.-1212. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al.: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin inpatients with symptomatic overactive bladder. BJU Int. 2004; 93: 303-10.) |
P = 0.32 |
OABSS ± SD |
28.7 ± 1.5 (2626. Roehrborn CG: Definition of at-risk patients: baseline variables. BJU Int. 2006; 97: 7-11; discussion 21-2.
27. Martín-Merino E, García-Rodríguez LA, Massó-González EL, Roehrborn CG: Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009; 182: 1442-8.
28. Layton D, Pearce GL, Shakir SA: Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 2001; 24: 703-13.
29. Wagg A, Compion G, Fahey A, Siddiqui E: Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012; 110: 1767-74.
30. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I: Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol. 1999; 162: 376-82.
31. Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O and for the TAABO Study Group: Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha-blocker Combined with Anticholinergics. LUTS: Lower Urinary Tract Symptoms, 2011; 3: 29-35.-3232. Bae WJ, Bae JH, Choi YS, Kim SJ, Cho HJ, Hong SH, et al.: Long-term alpha-blockers and anticholinergic combination treatment for men with lower urinary tract symptoms in real-lifepractice. Int Urol Nephrol. 2012; 44: 1077-84.) |
26.4 ± 1.2 (2323. Abdel-Aziz KF, Lemack GE: Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep. 2002; 3: 445-51.
24. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006; 49: 651-8.
25. Armitage J, Emberton M: The role of anticholinergic drugs in men with lower urinary tract symptoms. Curr Opin Urol. 2008; 18: 11-5.
26. Roehrborn CG: Definition of at-risk patients: baseline variables. BJU Int. 2006; 97: 7-11; discussion 21-2.
27. Martín-Merino E, García-Rodríguez LA, Massó-González EL, Roehrborn CG: Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009; 182: 1442-8.
28. Layton D, Pearce GL, Shakir SA: Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 2001; 24: 703-13.
29. Wagg A, Compion G, Fahey A, Siddiqui E: Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012; 110: 1767-74.
30. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I: Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol. 1999; 162: 376-82.-3131. Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O and for the TAABO Study Group: Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha-blocker Combined with Anticholinergics. LUTS: Lower Urinary Tract Symptoms, 2011; 3: 29-35.) |
28.2 ± 2.4 (2424. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006; 49: 651-8.
25. Armitage J, Emberton M: The role of anticholinergic drugs in men with lower urinary tract symptoms. Curr Opin Urol. 2008; 18: 11-5.
26. Roehrborn CG: Definition of at-risk patients: baseline variables. BJU Int. 2006; 97: 7-11; discussion 21-2.
27. Martín-Merino E, García-Rodríguez LA, Massó-González EL, Roehrborn CG: Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009; 182: 1442-8.
28. Layton D, Pearce GL, Shakir SA: Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 2001; 24: 703-13.
29. Wagg A, Compion G, Fahey A, Siddiqui E: Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012; 110: 1767-74.
30. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I: Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol. 1999; 162: 376-82.
31. Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O and for the TAABO Study Group: Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha-blocker Combined with Anticholinergics. LUTS: Lower Urinary Tract Symptoms, 2011; 3: 29-35.-3232. Bae WJ, Bae JH, Choi YS, Kim SJ, Cho HJ, Hong SH, et al.: Long-term alpha-blockers and anticholinergic combination treatment for men with lower urinary tract symptoms in real-lifepractice. Int Urol Nephrol. 2012; 44: 1077-84.) |
12.9 ± 1.9 (1111. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC: The results of prostatectomy: symptomatic and urodynamic analysis of 152 patients. J Urol. 1979; 121: 640-2.
12. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al.: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin inpatients with symptomatic overactive bladder. BJU Int. 2004; 93: 303-10.
13. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20: 327-36.
14. Miller SW, Miller MS: Urological disorders in men: urinary incontinence and benign prostatic hyperplasia. J Pharm Pract. 2011; 24: 374-85.
15. Polido Júnior A, Costa JM, Munhoz T, Sampaio FJ, Cardoso LE, Amaro JL: Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusoroveractivity. Int Urogynecol J. 2010; 21: 1539-44.
16. Gollar KM, Young DG, Bailen J, He W, Forero-Schwanhaeuser S: Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients byduration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urol Nurs. 2012; 32: 38-46, 50.
17. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z: Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65: 487-507.
18. H Saito, Takumi Y, Hiroyuki O, Takashi M, Toshiyuki M, Shin'ichi T, et al.: A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999; 12: 525-36.-1919. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169: 2253-6) |
P < 0.05 |
PVR ± SD |
70.5 ± 5.5 (65-76) |
51.5 ± 2.4 (49-60) |
68 ± 4 (64-72) |
50 ± 2 (45-54) |
P = 0.41 |